Calgary-Developed Wound Gel Sees Front-Line Use in Ukraine After Defence Department Origins

Innovation Moves from Canadian Defence Funding to Ukrainian Battlefields

A specialized wound and burn treatment developed in Calgary is currently being utilized on front lines in Ukraine to treat soldiers and civilians. Initially supported by a 2020 grant from Canada's Department of National Defence, the product—known as NanoSALV Catalytic—was granted Health Canada approval in 2022 and initially evaluated for treating unhoused populations in local encampments.

Details regarding the deployment and results of the treatment were presented at the CAN Health Network Annual Conference in Toronto.

Application and Medical Impact

Developed by Calgary-based NanoTess, the treatment consists of a catalytic substance suspended in a lightweight, non-flammable gel that can be applied directly to injuries. According to company co-founder and CEO Megan Leslie, the product can be transported via drone to front-line areas and administered by individuals with minimal medical training.

The gel utilizes nanomaterials designed to assist the body's natural healing processes by reducing the energy required for tissue repair while also targeting infection-causing micro-organisms. Since becoming available on the Ukrainian front lines in June, the treatment has been administered to approximately 6,000 wounded individuals.

Hailie Uren, an Australian clinical pharmacist working with the Ukrainian Ministry of Health in eastern Ukraine, noted that the product helps manage high patient volumes in resource-constrained environments where a single nurse may be responsible for dozens of patients.

Practical Implications and Domestic Context

Medical professionals have noted that products facilitating independent healing can reduce strain during mass casualty events. Dr. Eric Fung, an Alberta-based surgeon with experience in Ukraine, pointed out that efficient wound management aids in patient throughput during surges in hospital admissions.

What is Confirmed Versus Unknown

Confirmed:

• NanoSALV Catalytic was developed by Calgary-based NanoTess, with initial funding from Canada's Department of National Defence in 2020.
• The product received Health Canada approval in 2022 and was deployed to the Ukrainian front lines starting in June.
• Officials report the gel has been used to treat roughly 6,000 wounded soldiers and civilians.
• The results were presented at the CAN Health Network Annual Conference in Toronto.

Unknown:

• Specific details regarding long-term clinical trial metrics beyond the reported front-line usage figures were not detailed in the available records.
• Comprehensive logistics data concerning drone delivery frequencies remain unspecified.

How Readers Can Verify

Readers can review the original reporting and official announcements through the CBC News Report. Further inquiries regarding the technology can be directed through the NanoTess corporate communications channels or the CAN Health Network public archive.